Latest & greatest articles for myocardial infarction

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on myocardial infarction or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on myocardial infarction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for myocardial infarction

21. Myocardial infarction

Myocardial infarction Top results for myocardial infarction - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search (...) box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for myocardial infarction The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic

Trip Latest and Greatest2018

22. High-Sensitivity Troponins and Outcomes After Myocardial Infarction

High-Sensitivity Troponins and Outcomes After Myocardial Infarction 29880121 2018 06 08 1558-3597 71 23 2018 Jun 12 Journal of the American College of Cardiology J. Am. Coll. Cardiol. High-Sensitivity Troponins and Outcomes After Myocardial Infarction. 2616-2624 S0735-1097(18)34402-4 10.1016/j.jacc.2018.03.515 It remains unknown how the introduction of high-sensitivity cardiac troponin T (hs-cTnT) has affected the incidence, prognosis, and use of coronary angiographies and revascularizations (...) in patients with myocardial infarction (MI). The aim of this study was to investigate how the incidence of MI and prognosis after a first MI was affected by the introduction of hs-cTnT. In a cohort study, the authors included all patients with a first MI from the Swedish National Patient Registry from 2009 to 2013. Cox regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for risk of all-cause mortality, reinfarction, coronary angiographies, and revascularizations

EvidenceUpdates2018

23. Myocardial infarction

Myocardial infarction Autosynthesis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search

Trip Evidence Maps2018

25. Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis

Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis 29799995 2018 05 25 2168-6114 2018 May 21 JAMA internal medicine JAMA Intern Med Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis. 10.1001/jamainternmed.2018.0850 Treatment with aldosterone antagonists is recommended (...) and has been shown to have beneficial effects in patients with ST-segment elevation myocardial infarction (STEMI) and left ventricular ejection fraction (LVEF) less than 40%. However, the role of aldosterone antagonists in patients with ejection fraction greater than 40% or without congestive heart failure is not well known. To perform a systematic review and meta-analysis using standard techniques to determine the role of therapy with aldosterone antagonists in this patient population. PubMed, Embase

EvidenceUpdates2018

26. Effect of the Metabolic Syndrome on Outcomes in Patients Aged <50 Years Versus >50 Years With Acute Myocardial Infarction

Effect of the Metabolic Syndrome on Outcomes in Patients Aged <50 Years Versus >50 Years With Acute Myocardial Infarction 29729896 2018 05 06 1879-1913 2018 Apr 11 The American journal of cardiology Am. J. Cardiol. Effect of the Metabolic Syndrome on Outcomes in Patients Aged <50 Years Versus >50 Years With Acute Myocardial Infarction. S0002-9149(18)30856-7 10.1016/j.amjcard.2018.03.366 The presence of metabolic syndrome (MS) is associated with an increased risk of cardiovascular disease (...) morbidity and mortality. Moreover, data are lacking on the association of MS with clinical outcomes in young adults with acute myocardial infarction (AMI). This study was a retrospective analysis of 2,082 patients with AMI who underwent percutaneous coronary intervention. The term young was defined as age <50 years. The prevalence of patients aged <50 years was 18.4%. Among those patients, 43.4% had MS. The highest incidence of long-term major adverse cardiac and cerebral events was in old patients

EvidenceUpdates2018

27. Nitric oxide for inhalation in ST-elevation myocardial infarction (NOMI): a multicentre, double-blind, randomized controlled trial

Nitric oxide for inhalation in ST-elevation myocardial infarction (NOMI): a multicentre, double-blind, randomized controlled trial 29800130 2018 05 25 1522-9645 2018 May 24 European heart journal Eur. Heart J. Nitric oxide for inhalation in ST-elevation myocardial infarction (NOMI): a multicentre, double-blind, randomized controlled trial. 10.1093/eurheartj/ehy232 Inhalation of nitric oxide (iNO) during myocardial ischaemia and after reperfusion confers cardioprotection in preclinical studies (...) via enhanced cyclic guanosine monophosphate (cGMP) signalling. We tested whether iNO reduces reperfusion injury in patients with ST-elevation myocardial infarction (STEMI; NCT01398384). We randomized in a double-blind, placebo-controlled study 250 STEMI patients to inhale oxygen with (iNO) or without (CON) 80 parts-per-million NO for 4 h following percutaneous revascularization. Primary efficacy endpoint was infarct size as a fraction of left ventricular (LV) size (IS/LVmass), assessed by delayed

EvidenceUpdates2018

28. Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial) 29627109 2018 04 08 1879-1913 2018 Mar 15 The American journal of cardiology Am. J. Cardiol. Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). S0002-9149(18)30266-2 10.1016/j.amjcard.2018.02.030 Diabetes mellitus (DM) is a known risk factor for myocardial infarction (MI (...) ); however, data regarding MI subtypes in people with diabetes are limited. In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (n = 9,340), liraglutide significantly reduced the risk of major adverse cardiovascular (CV) events (composite of CV death, nonfatal MI, or nonfatal stroke) versus placebo in patients with type 2 DM and high CV risk. Liraglutide also reduced risk of first MI (292 events with liraglutide vs 339 with placebo). This post hoc

EvidenceUpdates2018

29. Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction

Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction 29695512 2018 04 26 1468-201X 2018 Apr 25 Heart (British Cardiac Society) Heart Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction. heartjnl-2018-312950 10.1136/heartjnl-2018-312950 Two recent randomised trials studied the benefit of mineralocorticoid receptor antagonists (MRAs) in ST-segment elevation myocardial infarction (STEMI) irrespective or (...) in absence of heart failure. The studies were both undersized to assess hard clinical endpoints. A pooled analysis was preplanned by the steering committees. We conducted a prespecified meta-analysis of patient-level data of patients with STEMI recruited in two multicentre superiority trials, randomised within 72 hours after symptom onset. Patients were allocated (1:1) to two MRA regimens: (1) an intravenous bolus of potassium canrenoate (200 mg) followed by oral spironolactone (25 mg once daily) versus

EvidenceUpdates2018

30. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis

Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis 29674321 2018 05 06 1468-2060 2018 Apr 19 Annals of the rheumatic diseases Ann. Rheum. Dis. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. annrheumdis-2018-213089 10.1136/annrheumdis-2018-213089 Spondyloarthritis (SpA) is associated with an increased risk (...) of myocardial infarction (MI) due to underlying inflammation and possibly due to medications such as certain non-steroidal anti-inflammatory drugs (NSAIDs). We sought to describe MI risk among patients with SpA who were prescribed NSAIDs, and to compare the pattern of risk in SpA with that in osteoarthritis (OA). Nested case-control studies were performed using The Health Improvement Network (THIN). Underlying cohorts included adults with incident SpA or OA who had > 1 NSAID prescription and no history of MI. Within

EvidenceUpdates2018

31. Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials

Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials 29599378 2018 03 30 1468-201X 2018 Mar 29 Heart (British Cardiac Society) Heart Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials. heartjnl-2018-313089 10.1136/heartjnl-2018-313089 Although oxygen therapy has been used for over a century in the management of patients (...) with suspected acute myocardial infarction (AMI), recent studies have raised concerns around the efficacy and safety of supplemental oxygen in normoxaemic patients. To synthesise the evidence from randomised controlled trials (RCTs) that investigated the effects of supplemental oxygen therapy compared with room air in patients with suspected or confirmed AMI. For this aggregate data meta-analysis, multiple databases were searched from inception to 30 September 2017. RCTs with any length of follow-up and any

EvidenceUpdates2018

32. Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis

Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis 29548675 2018 03 17 1879-1913 2018 Feb 12 The American journal of cardiology Am. J. Cardiol. Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis. S0002-9149(18)30189-9 10.1016/j.amjcard.2018.01.044 There are still debates on the association of increased (...) cardiovascular risk with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with rheumatoid arthritis (RA) because of inconsistent results. Therefore, our study aims to evaluate the transient effects of selective and nonselective NSAIDs on the risk of stroke and acute myocardial infarction (AMI) in patients with RA. We conducted a case-crossover study of 5,921 stroke or AMI patients with co-morbidity of RA. All cases were identified from the Taiwan National Health Insurance Database between

EvidenceUpdates2018

33. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014)

No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014) 29122546 2018 04 07 1528-0012 154 4 2018 03 Gastroenterology Gastroenterology No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014). 861-873.e6 S0016-5085(17)36330-8 10.1053/j.gastro.2017.10.042 Proton pump inhibitors (PPIs) are (...) commonly used medications. Recent studies reported an increased risk of acute myocardial infarction (MI) in PPI users vs non-users. We evaluated MI risk associated with PPIs compared with histamine-2 receptor antagonists (H2RAs) in privately insured adults in the United States. Using administrative claims from commercial and Medicare Supplemental plans (2001-2014), we compared risk of MI in patients who started a new prescription for PPIs vs H2RAs. Enrollees were followed from their first prescription

EvidenceUpdates2018

34. Oxygen Therapy in Patients with Acute Myocardial Infarction: A Systemic Review and Meta-Analysis

Oxygen Therapy in Patients with Acute Myocardial Infarction: A Systemic Review and Meta-Analysis 29355510 2018 03 08 1555-7162 2018 Mar 05 The American journal of medicine Am. J. Med. Oxygen Therapy in Patients with Acute Myocardial Infarction: A Systemic Review and Meta-Analysis. S0002-9343(18)30017-2 10.1016/j.amjmed.2017.12.027 Oxygen therapy is frequently used for patients with acute myocardial infarction. The aim of this study is to perform a systematic review and meta-analysis to compare (...) the outcomes of oxygen therapy versus no oxygen therapy in post-acute myocardial infarction settings. A systematic search of electronic databases was conducted for randomized studies, which reported cardiovascular events in oxygen versus no oxygen therapy. The evaluated outcomes were all-cause mortality, recurrent coronary events (ischemia or myocardial infarction), heart failure, and arrhythmias. Summary-adjusted risk ratios (RRs) were calculated by the random effects DerSimonian and Laird model. The risk

EvidenceUpdates2018

35. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study.

Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. OBJECTIVE: To compare the risk of in-hospital mortality associated with haloperidol compared with atypical antipsychotics in patients admitted to hospital with acute myocardial infarction. DESIGN: Cohort study using a healthcare database. SETTING: Nationwide sample of patient data from more than 700 hospitals across the United States. PARTICIPANTS: 6578 (...) medical patients aged more than 18 years who initiated oral haloperidol or oral atypical antipsychotics (olanzapine, quetiapine, risperidone) during a hospital admission with a primary diagnosis of acute myocardial infarction between 2003 and 2014. MAIN OUTCOME MEASURE: In-hospital mortality during seven days of follow-up from treatment initiation. RESULTS: Among 6578 patients (mean age 75.2 years) treated with an oral antipsychotic drug, 1668 (25.4%) initiated haloperidol and 4910 (74.6%) initiated

BMJ2018

36. Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction

Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction 29463612 2018 02 21 1468-201X 2018 Feb 20 Heart (British Cardiac Society) Heart Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction. heartjnl-2017-312698 10.1136/heartjnl-2017-312698 During primary percutaneous coronary intervention (PCI), a concurrent chronic total occlusion (CTO) is found in 10% of patients with ST-elevation (...) myocardial infarction (STEMI). Long-term benefits of CTO-PCI have been suggested; however, randomised data are lacking. Our aim was to determine mid-term and long-term clinical outcome of CTO-PCI versus CTO-No PCI in patients with STEMI with a concurrent CTO. The Evaluating Xience and left ventricular function in PCI on occlusiOns afteR STEMI (EXPLORE) was a multicentre randomised trial that included 302 patients with STEMI after successful primary PCI with a concurrent CTO. Patients were randomised to either CTO

EvidenceUpdates2018

37. Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation

Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation 29447733 2018 02 15 1558-3597 71 7 2018 Feb 20 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. 727-735 S0735-1097(17)41924-3 10.1016/j.jacc.2017.12.011 Stroke can occur after myocardial infarction (MI) in the absence of atrial fibrillation (AF). This study (...) sought to identify risk factors (excluding AF) for the occurrence of stroke and to develop a calibrated and validated stroke risk score in patients with MI and heart failure (HF) and/or systolic dysfunction. The datasets included in this pooling initiative were derived from 4 trials: CAPRICORN (Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left Ventricular Dysfunction), OPTIMAAL (Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan), VALIANT

EvidenceUpdates2018

38. Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial.

Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial. Importance: Wide heterogeneity exists in acute myocardial infarction treatment and outcomes in India. Objective: To evaluate the effect of a locally adapted quality improvement tool kit on clinical outcomes and process measures in Kerala, a southern Indian state. Design, Setting, and Participants: Cluster randomized, stepped-wedge (...) clinical trial conducted between November 10, 2014, and November 9, 2016, in 63 hospitals in Kerala, India, with a last date of follow-up of December 31, 2016. During 5 predefined steps over the study period, hospitals were randomly selected to move in a 1-way crossover from the control group to the intervention group. Consecutively presenting patients with acute myocardial infarction were offered participation. Interventions: Hospitals provided either usual care (control group; n = 10 066 participants

JAMA2018

39. Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock

Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock Hilde L. Orrem 1 , Per H. Nilsson 1,2,3 , Søren E. Pischke 1,4 , Guro Grindheim 4 , Peter Garred 5 , Ingebjørg Selje?ot 6,7,10 ,Trygve Husebye 7,10,11 , Pål Aukrust 2,8,9,10 (...) of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; 11 Center of Heart Failure Research, University of Oslo, Oslo, Norway; 12 Research Laboratory Nordland Hospital, Bodø and K.G. Jebsen TREC, University of Tromsø,Tromsø, Norway; 13 Centre of Molecular In?ammation Research, Norwegian University of Science and Technology,Trondheim, Norway Abstract Aims Heart failure (HF) is an impending complication to myocardial infarction. We hypothesized that the degree of comple- ment activation

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

40. Meta-Analysis of Culprit-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease

Meta-Analysis of Culprit-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease 29304995 2018 02 08 1879-1913 121 5 2018 Mar 01 The American journal of cardiology Am. J. Cardiol. Meta-Analysis of Culprit-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease. 529-536 S0002-9149(17)31847-7 10.1016 (...) /j.amjcard.2017.11.022 Recently, several randomized controlled trials (RCT) in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD) have compared a strategy of routine multivessel percutaneous coronary intervention (PCI) performed either as a single procedure or as staged procedures to culprit-only PCI. All of these trials have been underpowered for clinical end points. We searched PubMed, Embase, and Cochrane Central Register of Controlled Trials for RCT

EvidenceUpdates2018